Anavex joins ACCESS-AD, initiative for therapeutic approaches for Alzheimer’s

Anavex (AVXL) Life Sciences announced its participation as a key industry partner in ACCESS-AD, a European initiative designed to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer’s disease across real-world clinical settings. The five year program is funded by the European Commission’s Innovative Health Initiative. “We are pleased that blarcamesine will be evaluated within ACCESS-AD’s innovative precision-medicine framework,” said Christopher U. Missling, PhD, President & CEO of Anavex. “This initiative represents a unique opportunity to integrate advanced biomarker data and digital tools with a therapy that is intentionally designed to be accessible, scalable and compatible within diverse healthcare environments. We look forward to contributing to a future in which personalised care is available to all people living with Alzheimer’s disease.”